HC Wainwright reaffirmed their buy rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note published on Tuesday. The firm currently has a $17.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on TTPH. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 5th. BMO Capital Markets upped their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an outperform rating in a research report on Wednesday, October 4th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 1st. Needham & Company LLC restated a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $13.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up $0.31 during trading on Tuesday, reaching $6.15. 539,148 shares of the company’s stock were exchanged, compared to its average volume of 388,858. Tetraphase Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.58) EPS. sell-side analysts expect that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current year.

In related news, Director L Patrick Gage purchased 3,880 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jacques Dumas sold 8,750 shares of the stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $108,000. UBS Group AG increased its holdings in Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 387 shares in the last quarter. AXA purchased a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at about $132,000. Finally, Voya Investment Management LLC increased its holdings in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares in the last quarter. Hedge funds and other institutional investors own 58.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-tetraphase-pharmaceuticals-ttph/1754246.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.